Multiple Myeloma Non-Hodgkin Lymphoma CLL AML ALL Other Topics
Issue Spotlight on ASH 2020
CAR T-Cell Engineering May Enhance Responses in Large B-Cell Lymphoma
Stanford University researchers have identified tumor-specific factors driving inherent or acquired resistance to chimeric antigen receptor (CAR) T cells in large B-cell lymphomas (LBCL). They have also discovered that CD58 status is an important biomarker for durable response to CAR T cells.
Relapsed Hematologic Malignancy Patients Vulnerable to COVID-19
The ASH Research Collaborative COVID-19 Registry for Hematology international registry, launched in April 2020, provides near real-time data to hematologists and other clinicians who are caring for patients amid the COVID-19 pandemic. It offers important insights into which patients are most vulnerable to severe illness and death.
An Analysis of Real-World Patients With Chronic Lymphocytic Leukemia
“Chronic lymphocytic leukemia is the most common leukemia among adults in the U.S.,” noted Lori A. Leslie, MD, of John Theurer Cancer Center at Hackensack University Medical Center. “Ibrutinib is a once-daily Bruton's tyrosine kinase inhibitor that has shown significant survival benefit over chemo and/or immunotherapy in a randomized Phase III study in previously untreated or relapsed/refractory CLL or SLL.”
Young Black acute myeloid leukemia (AML) patients have poorer overall survival (OS) than younger White AML patients, according to research presented at the 2020 ASH Annual Meeting (Abstract 6). Mutational differences between Black and White AML patients might be an indicator for differences in AML tumor biology that could potentially provide an explanation for this survival disparity.
Inner City Socioeconomic Disparities Influence AML Survival
Poor minority patients who live in segregated neighborhoods have a higher risk of dying from acute myeloid leukemia (AML) than their more affluent, White counterparts. Non-Hispanic Black and Hispanic patients with AML have higher mortality rates than non-Hispanic White patients despite lower incidence, more favorable genetics, and a younger age at presentation.
From the Issue
Combination Treatment Approach Shows Promise for R/R Multiple Myeloma
“The ALGONQUIN study was designed to address the urgent need to improve outcomes of patients treated with pomalidomide and dexamethasone that induces overall response rates of only 30 percent and progression-free survival of 4 months,” noted study author Suzanne Trudel, MD, MSC, FRCPC, a clinician scientist in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre, University of Toronto.
The COVID-19 Impact On Hematology/Oncology Fellowships
Oncology Times connected with Nino Balanchivadze, MD, and Vijayalakshmi Donthireddy, MD, authors of “Hematology/Oncology Fellowship Emergency Restructuring in Response to the COVID-19 Pandemic—Henry Ford Hospital, Michigan” to get their advice on how fellows can move forward in their careers after COVID-19.